Search Thermo Fisher Scientific
- Contact Us
- Quick Order
-
Don't have an account ? Create Account
Search Thermo Fisher Scientific
Studies aimed at leveraging an individual’s own immune system as a potential strategy toward the advancement of precision oncology has been a shared goal of scientists for many years. However, the complexities of tumor–immune interactions warrant a multidimensional approach to facilitate well-designed translational research studies and interpretation of results. Genomic analysis solutions based on next-generation sequencing (NGS) can be powerful tools to help gain significant insights in translational and clinical research.
Order now Request more info Request a quote
Analyzing the immune repertoire to capture the diversity of T cell receptor (TCR) rearrangements can help you make significant progress in immuno-oncology research. The Oncomine TCR Beta-LR Assay, provides researchers with a rapid, long-read NGS tool for studying the complexity of cellular immunology. This comprehensive solution enables you to:
Discover immune response biomarkers—accurately measure T cell repertoire diversity and clonal expansion, and identify antigen-specific T cells to accelerate translational research
Investigate markers for immune-mediated adverse events (IMAEs)—analyze all three complementarity-determining regions (CDR1, 2, and 3) for allele-specific polymorphisms that may be linked to autoimmune diseases and IMAEs
Optimize the function and manufacture of potentially therapeutic T cells—characterize TCR beta chain sequences and optimize the manufacture of genetically engineered T cells
Deciphering the cancer immunity cycle through next generation sequencing
Advancing precision immunotherapy through next-generation sequencing of T cell receptors, Part I
Advancing precision immunotherapy through next-generation sequencing of T cell receptors, Part II
Dr. Prof. Jose Carlos Machado Ipatimup, Medical Faculty Porto, Portugal
The concept that the immune system plays a critical role in anti-tumor responses has been demonstrated and, more recently, immune checkpoint therapy has started a revolution in the field of oncology research. Several research studies are ongoing to identify appropriate biomarkers, and a multi-biomarker approach is seen as the only path to advance immunotherapy research.
Manual library construction is followed by automated template preparation using the Ion Chef System. Sequencing is performed on the Ion S5 System with data analysis using Ion Reporter Software.
Based on robust, highly referenced Ion AmpliSeq technology, our NGS solution has been carefully designed to significantly improve your turnaround time—go from sample to analysis in as little as 48 hours (Figure 1). The Oncomine TCR Beta-LR Assay, is comprehensive with up to 400 bp read-length amplicons for complete characterization of CDR1, CDR2, and CDR3 (Figure 2). It is highly accurate with mRNA-based sequencing and exerts extremely low PCR-driven primer bias.
Data security—you have full control of your data (with no service model or additional fees) and full transparency in analysis, and your TCR sequences stay with you
Accuracy—with RNA as a starting point, you can interrogate productive rearrangement of TCR beta chain genes and benefit from low substitution error rates achieved on the Ion S5 System
Low input requirement—create your Ion AmpliSeq library from a range of input amounts (10 ng–1 μg), depending on your sample constraints and application preferences
Poster: TCRB chain convergence in chronic cytomegalovirus infection and cancer
Download flyer
Flyer-Ion AmpliSeq Immune Repertoire Assay Plus, TCR β
Poster: Peripheral blood TCRB repertoire convergence and clonal expansion predict response to anti-CTLA-4 monotherapy for cancer
Poster: Peripheral blood TCRB chain convergence predicts response to immunotherapy in advanced melanoma
Poster: TRBV polymorphism predicts adverse events during checkpoint blockade immunotherapy
Poster: Evaluation of therapeutic T cell manufacture using long amplicon TCRβ immune repertoire sequencing
Flyer: Multidimensional NGS solutions enable tumor-immune insights within IO research
Poster: Targeted T-cell receptor beta immune repertoire sequencing in several FFPE tissue types
Poster: Peripheral Blood TCRB Chain Convergence Predicts Response to Dendritic Cell-Based Immunotherapy in Advanced-Stage Melanoma Patients
Poster: Peripheral blood TCRB repertoire convergence and clonal expansion predict response to anti-CTLA-4 monotherapy for cancer
For Research Use Only. Not for use in diagnostic procedures.